Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11392
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMitchell, Paul L Ren
dc.contributor.authorBroad, Adamen
dc.contributor.authorRosenthal, Mark Aen
dc.contributor.authorGalettis, Peteren
dc.contributor.authorAbraham, Ricken
dc.contributor.authorBurns, Ivonen
dc.contributor.authorClarke, Stephenen
dc.contributor.authorMilner, Alvinen
dc.contributor.authorDiiulio, Julianaen
dc.contributor.authorLinks, Matthewen
dc.date.accessioned2015-05-16T00:58:58Z
dc.date.available2015-05-16T00:58:58Z
dc.date.issued2011-05-23en
dc.identifier.citationAsia-pacific Journal of Clinical Oncology 2011; 7(4): 376-84en
dc.identifier.govdoc22151988en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11392en
dc.description.abstractThis multicentre phase II trial examined the combination of gemcitabine and oxaliplatin in patients with advanced non-small cell lung cancer (NSCLC). The effect of sequence administration was randomized and pharmacokinetics (PK) assessed.Eligible patients had stage IIIB or IV or recurrent NSCLC, no prior chemotherapy, World Health Organization performance status ≤2 and measurable disease. Treatment comprised: gemcitabine (1250 mg/m(2)) and oxaliplatin (70 mg/m(2)), each given on days 1 and 8 of a 21-day cycle. Patients were randomized 1:1 to the sequencing of the two drugs for the duration of their treatment. The primary end-point was response rate (RR). Secondary end-points included progression-free survival (PFS), overall survival (OS), toxicity, PK and the effect of drug sequencing.A total of 46 patients were enrolled of whom 43 were evaluable for response. Overall 13 patients (30%) achieved a partial response, PFS was 4.2 months (95% CI 2.8-5.8 months), and OS was 6.8 months (95% CI 4.4-10.1 months). There was only one case of grade 3 neurosensory toxicity despite a median cumulative oxaliplatin dose in excess of 500 mg/m(2) . No differences in clinical or PK end-points were observed between the two different sequencing arms.This oxaliplatin and gemcitabine schedule has shown activity in advanced NSCLC with modest toxicity. Neither clinical nor PK outcomes were influenced by the sequencing of these agents, although definite conclusions are limited by small patient numbers. The favorable toxicity profile of this doublet, in light of an encouraging RR, warrants its further investigation in NSCLC.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAntineoplastic Combined Chemotherapy Protocols.administration & dosage.pharmacokineticsen
dc.subject.otherCarcinoma, Non-Small-Cell Lung.drug therapy.metabolismen
dc.subject.otherDeoxycytidine.administration & dosage.analogs & derivativesen
dc.subject.otherDisease-Free Survivalen
dc.subject.otherDrug Administration Scheduleen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherKaplan-Meier Estimateen
dc.subject.otherLung Neoplasms.drug therapy.metabolismen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherOrganoplatinum Compounds.administration & dosageen
dc.subject.otherSurvival Analysisen
dc.titleRandomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleAsia-Pacific journal of clinical oncologyen
dc.identifier.affiliationDepartment of Medical Oncology, Austin Hospital, Queensland, Australiaen
dc.identifier.doi10.1111/j.1743-7563.2011.01390.xen
dc.description.pages376-84en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/22151988en
dc.type.austinJournal Articleen
local.name.researcherMitchell, Paul L R
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.